SFX by Ex Libris Inc.

Title:	A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma
Source:	Science [0036-8075] Shuai, K yr:1993

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	SHUAI, K. "INTERFERON ACTIVATION OF THE TRANSCRIPTION FACTOR STAT91 INVOLVES DIMERIZATION THROUGH SH2-PHOSPHOTYROSYL PEPTIDE INTERACTIONS." Cell 76.5: 821-828.
description	2.	SCHINDLER, C. "INTERFERON-DEPENDENT TYROSINE PHOSPHORYLATION OF A LATENT CYTOPLASMIC TRANSCRIPTION FACTOR." Science 257.5071: 809-813.
description	3.	Park, S. "Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry." Breast 21.1 (2012): 50-57.
description	4.	Horvath, C. "Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex." Molecular and cellular biology 16.12 (1996): 6957-6964.
description	5.	Wen, Z.. "Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation." Cell 82.2 (1995): 241-250.
description	6.	Mao, X. "Structural bases of unphosphorylated STAT1 association and receptor binding." Molecular cell 17.6 (2005): 761-71.
description	7.	Heim, J E H. "Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway." Science 267.5202 (1995): 1347-9.
description	8.	HORVATH, C. "A STAT PROTEIN DOMAIN THAT DETERMINES DNA-SEQUENCE RECOGNITION SUGGESTS A NOVEL DNA-BINDING DOMAIN." Genes & development 9.8 (1995): 984-994.
description	9.	Pawson, Tony, T. "Protein modules and signalling networks." Nature 373.6515 (1995): 573-580.
description	10.	Stark, G R R. "Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins." Science 264.5164 (1994): 1415-21.
description	11.	Foulkes, W. "Triple-Negative Breast Cancer." The New England journal of medicine 363.20 (2010): 1938-1948.
description	12.	Ramage, W R. "Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report." The Journal of steroid biochemistry and molecular biology 86.3 (2003): 239-244.
description	13.	Mazouni, C. "Outcome in breast molecular subtypes according to nodal status and surgical procedures." The American journal of surgery (2013).
description	14.	MartinezMoczygemba, M. "Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3." Journal of biological chemistry 272.32 (1997): 20070-20076.
description	15.	Zhang, T. "The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6." Molecular and cellular biology 20.19 (2000): 7132-7139.
description	16.	Collins, L. C. C. "Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer." Breast cancer research and treatment 131.3 (2011): 1061-1066.
description	17.	Rebouissou, S. "Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours." Nature 457.7226 (2009): 200-4.
description	18.	Chattopadhyay,, Saket, S. "Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles." Biochemical and biophysical research communications 389.3 (2009): 484-489.
description	19.	Yu, C.-L. L. "Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein." Science 269.5220 (1995): 81-83.
description	20.	Zhong, Z. "Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6." Science 264.5155 (1994): 95-8.